AbbVie's Ibrutinib improves survival for treatment chronic lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial Print
By Josh Gee   
Thursday, 04 June 2015 18:57

Pharmacyclics LLC, an AbbVie Inc. (NYSE:ABBV), has confirmed that ibrutinib improved progression-free survival and multiple secondary endpoints which includes overall survival and overall response rate  in treating patients suffering from chronic lymphocytic leukemia.

 

RESONATE-2 is randomized and open-label study that makes assessment of use of ibrutinib as compared to chlorambucil in treating CLL/SLL patients with ages of 65 years or more.

 

The trial is the primary head-to-head trial one evaluating safety and efficacy of ibrutinib as compared to traditional chemotherapy.

 

IMBRUVICA is jointly developed as well as commercialized by Janssen Biotech and Pharmacyclics.

 

Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics, opined that the firm is excited on finding of RESONATE-2 in partnership with Jannsen and it is looking forward on displaying results from potentially transformative study for CLL patients. James added that the results from IMBRUVICA study for front-line CLL patients may help in supporting future treatment paradigms.

 

Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer at AbbVie, opined that the firm has made a lot of progress in treating CLL. He added that IMBRUVICA is demonstrating strong value and

that the firm is positive that it would move into front-line treatment setting leading to an alternative option for chemotherapy.

 

RESONATE-2 is Pharmacyclics-sponsored trial and

Error. Page cannot be displayed. Please contact your service provider for more details. (15)

its specific performance goals made in special protocol assessment with U.S. Food and
Drug Administration.

 

 

An SPA is an agreement with FDA stating that ongoing Phase III clinical trial design as well as other statistical analyses are agreeable to the agency for supporting an approval. The trial had 269 patients with CLL aged 65 years or more without any other treatment in U.S., EU and other regions. 




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1